Contributing Teams

AMP-AD: Arizona State University

The ASU team, led by Ben Readhead, uses multi-omic profiling, 3D-cerebral organoids and CRISPR-Cas9 approaches to understand the role of pathogens in the etiology and progression of Alzheimer's disease.

Ben Readhead
Elaine Lim
Qi Wang
Rigel Chan

AMP-AD: Columbia University - Rush University

The Columbia-Rush AMP-AD team, led by Philip De Jager and David Bennett, focuses on taking a systems biology approach to mine a unique set of deep clinical, paraclinical, pathologic, genomic, epigenomic, transcriptomic, proteomic, metabolic and single cell brain and blood data from more than 1000 subjects from two prospective cohort studies of aging and dementia. They use these data to identify genes, proteins, and pathways with critical roles in a range of traits that influence the function of the aging brain, including susceptibility Alzheimer's disease, the accumulation of aging-related neuropathologies, cognitive decline in older age, as well as resilience to the brain pathologies. Finally, the team then interrogates those genes in ex vivo and in vitro systems to determine their therapeutic potential.

Chris Gaiteri
Jishu Xu
Lei Yu
Shinya Tasaki
Tracy Young Pearce

AMP-AD: Duke University

The Duke AMP-AD team, led by Rima Kaddurah-Daouk, focuses on taking an integrated metabolomics-genetics-imaging systems approach to define network failures in Alzheimer's disease.

Andrew Saykin
Colette Blach
Gabi Kastenmuller
Gregory Louie
Jessie Tenenbaum
Matthias Arnold

AMP-AD: Emory University

The Emory AMP-AD team, led by Allan Levey, focuses on the generation and analysis of proteomic data to understand neurodegenerative disease. Targets nominated by the Emory team have been identified through the analysis of differential protein expression and co-expression network analysis.

Duc Duong
Eric Dammer
James Lah
Joshua Shulman
Nicholas Seyfried

AMP-AD: Harvard University - Massachusetts Institute of Technology

The Harvard-MIT AMP-AD 1.0 team, led by Bruce Yankner and Li-Huei Tsai, focuses on elucidating the regulatory role of the REST network in protecting aging neurons from age-related stressors, reducing neuroinflammation and preserving cognitive function.

AMP-AD: The Mayo Clinic - University of Florida - The Institute for Systems Biology

The Mayo-UFL-ISB AMP-AD team, led by Nilufer Ertekin-Taner, Todd Golde, Nathan Price, and Steven Younkin, includes three institutions: the University of Florida, the Institute for Systems Biology, and the Mayo Clinic Jacksonville. The focus of the team is to identify therapeutic targets within the innate immune signaling cascade in Alzheimer's disease that can be safely manipulated to provide disease modification.

Adelyn Tsai
Cory Funk
Mariet Allen
Minerva Carrasquillo
Ozkan Is
Stephanie Oatman
Yuhao (Harry) Min

AMP-AD: The Roussos Lab at the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai AMP-AD team lead by Panos Roussos, Vahram Haroutunian, John Fullard, Gabriel Hoffman, Donghoon Lee, and Jaro Bendl focuses on changes of immune markers underlying the etiology of Alzheimer's disease.

Christian Porras
Collin Spencer
David Bennett
Milos Pjanic
Prashant NM
Roman Kosoy
Xinyi Wang

AMP-AD: The Zhang Lab at the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai AMP-AD team lead by Eric Schadt, Bin Zhang, Jun Zhu, Michelle Ehrlich, Vahram Haroutunian, Samuel Gandy, Koichi Iijima, and Scott Noggle focuses on developing a multiscale network approach to elucidating the complexity of Alzheimer's disease.

Community Contributed: The Biodemography of Aging Research Unit (BARU) at Duke University

The team of the Biodemography of Aging Research Unit (BARU) at Duke University, led by Anatoliy Yashin, Svetlana Ukraintseva, Alexander Kulminski, Konstantin Arbeev, and Eric Stallard, focuses on advanced genetic association analyses combined with multi-level functional interpretation approaches, to identify genes and underlying physiological and pathological processes contributing to heterogeneous etiology of Alzheimer's disease and human longevity.

Anatoliy Yashin
Svetlana Ukraintseva
Alexander Kulminski
Eric Stallard
Konstantin Arbeev

Community Contributed: The Chang Lab at the University of Arizona

The Chang Team at the University of Arizona, led by Rui Chang, develops novel computational systems biology models to discover drug targets for in-silico precision medicine for AD. The target nominations are based on work performed by the Chang Team at the Icahn School of Medicine at Mt. Sinai.

Kuixi Zhu

Community Contributed: The Longo Lab at Stanford University

Dr. Longo and his research team are focused on elucidating mechanisms underlying neurodegenerative disorders and developing small molecule therapeutic strategies that target these mechanisms. Neurotrophins bind to multiple receptors (p75, TrkA-C) to modulate survival, functional and degenerative intracellular signaling and synaptic function. The Longo laboratory and collaborators pioneered the mechanistic principle that non-peptide small molecules targeting individual receptor epitopes (change to receptors) can activate or modulate neurotrophin receptors to produce distinctive biological effects capable of inhibiting disease mechanisms. This work has led to successful efficacy trials in many mouse models of neurodegenerative disorders including Alzheimer's, Huntington's, and Parkinson's diseases as well as spinal cord injury, traumatic brain injury, chemotherapy-induced neuropathy, ischemic stroke recovery, Rett syndrome, and epilepsy.

Resilience-AD: The Jackson Laboratory - Vanderbilt University Medical Center - University of Washington

The JAX-VUMC-UW team, led by Catherine Kaczorowski, Timothy Hohman and Mike MacCoss uses a systems genetics approach to discover mechanisms underlying cognitive resilience to Alzheimer's disease using a translationally relevant mouse panel that incorporates high-risk familial AD (FAD) mutations on a segregated background of genetic diversity (BXD panel). The AD-BXD mouse population exhibits wide variation in age at onset and progression of cognitive symptoms similar to those observed in patients with FAD mutations, as well as late-onset AD (LOAD). Cross-species integrative analyses of deep behavioral, neuropathologic, genomic, transcriptomic, proteomic, and single cell brain data are used to identify genes, proteins, and pathways with critical roles in nonpathological aging, as well as resilience to the brain pathologies induced by FAD mutations. Validation of candidate genes and proteins associated with cognitive resilience are evaluated for behavior, electrophysiological and neuropathological effects.

Resilience-AD: The Mayo Clinic

The Mayo Resilience-AD team is led by Dr. Nilufer Ertekin-Taner. The focus of the team is to identify precision medicine therapeutictargets and/or biomarkers for Alzheimer's disease through multiomics data generation.

Adelyn Tsai
Joseph Reddy
Mariet Allen
Minerva Carrasquillo
Ozkan Is
Stephanie Oatman
Xue Wang
Yuhao (Harry) Min

TREAT-AD: Emory University - Sage Bionetworks - Structural Genomics Consortium

The mission of the Emory-Sage-Structural Genomics Consortium (SGC) TREAT-AD center is to diversify the portfolio of drug targets in Alzheimer's disease (AD). We aim to catalyze research into biological pathways that have been associated with disease from deep molecular profiling and bioinformatic evaluation of AD in the human brain within the National Institute on Aging's (NIA) Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD) consortium. Many of these potential AD drug targets are predicted to reside among the thousands of human proteins that historically have received little attention and for which there are few reagents, such as quality-verified antibodies, cell lines, assays or chemical probes. To catalyze their investigation, we are developing and openly distributing experimental tools, including chemical probes, for broad use in the evaluation of a diverse set of novel AD targets.

TREAT-AD: The Indiana University School of Medicine (IUSM) - Purdue

At the Indiana University School of Medicine (IUSM)-Purdue TREAT-AD center, our strategic goal is to integrate sophisticated capability for early drug discovery and contribute to a broader study of emerging Alzheimer's Disease (AD) target hypotheses and etiologies with the goal of generating new classes of potential therapeutics. Specifically, the group will establish itself as a strategic and operational partner for the National Institute on Aging (NIA) Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD) and Model Organism Development and Evaluation for Late Onset Alzheimer's Disease (MODEL-AD) initiatives. By design, this will provide drug discovery capability to bridge the foundational work in target discovery (AMP-AD) with newly discovered lead molecules characterized in AD animal models based on human pathology, genetics, and translational biomarkers (MODEL-AD). A key advantage and differentiated strength of the Center is the primary scientific coordination and administration through the Indiana University School of Medicine. Specifically, this concentrates a strong and long-standing commitment to neurodegenerative research through co-presence with the NIA-supported Indiana Alzheimer's Disease Center, the MODEL-AD consortium, and the Longitudinal Early Onset Alzheimer's Disease (LEAD) study.

Sage Bionetworks

Sage Bionetworks develops and maintains the Agora platform, and acts as the Data Coordinating Center for several NIA-funded Alzheimer's Disease research consortia, including AMP-AD, Model-AD, M2OVE-AD, and Resilience-AD. Sage is a nonprofit organization that partners with researchers, patients, and healthcare innovators to drive collaborative data-driven science to improve health. Sage helps advance biomedicine by making science more open, collaborative, and inclusive.

Abby Vander Lindon
Amelia Kallaher
Anthony Pena
Brad Macdonald
Jaclyn Beck
Jared Hendrickson
Jess Britton
Jesse Wiley
Jessica Malenfant
Jo Scanlan
Karina Leal
Khai Do
Laura Heath
Lawrence Yi
Ljubomir Bradic
Nicholas Lee
Stockard Simon
William Poehlman
Zoe Leanza